HOME >> BIOLOGY >> NEWS
New therapeutic insight into duchenne muscular dystrophy

In the April 1st issue of Genes & Development, Dr. Bruce Spiegelman (Dana Farber Cancer Institute) and colleagues identify a key genetic component of and possible therapeutic target for Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy, affecting about 1 in 3000 males each year. It is an X-linked recessive disease, in which mutations in the dystrophin gene causes progressive and degenerative muscle weakness. DMD is generally lethal by age 30.

Dr. Spiegelman and colleagues found that a protein called PGC-1alpha regulates the point of connection between the end of a motor neuron and a muscle fiber what researchers call the "neuromuscular junction." Electrical impulses travel through the neuromuscular junction, ultimately causing the muscle to contract. Previous research has shown that PGC-1alpha expression is induced by physical exercise and motor neuron activity, and mediates the anti-atrophic effects of nerve activity on muscle mass.

Dr. Spiegelman and colleagues analyzed the function of PGC-1alpha in a mouse model of DMD. They found that PGC-1alpha activates the expression of several genes that are aberrantly inactivated in DMD. In fact, by inducing PGC-1alpha expression in these transgenic mice, the scientists were able to improve DMD symptoms.

"These data clearly show that experimental elevation of PGC-1 alpha has therapeutic promise in an animal model of Duchene's muscular dystrophy. We hope this will lead eventually to therapeutics for a terrible disease for which there is no effective treatment at the present time," explains Dr. Spiegelman.


'"/>

Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
31-Mar-2007


Page: 1

Related biology news :

1. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer
2. From clinical cancer research: rethinking therapeutic cancer vaccine trials
3. Sensitivity to diverse range of chemotherapeutic drugs linked to common pathway
4. Small molecule derived from Rb2/p130 could act as cancer therapeutic
5. Sphingolipids with therapeutic ends
6. New therapeutic target for Alzheimers could lead to drugs without side effects
7. VBI research offers potential route to diabetes therapeutics
8. Quiet revolution may herald new RNA therapeutics
9. Scientists discover two-component lantibiotic with therapeutic potential
10. Potential new therapeutic target for asthma, allergies and cancer
11. Chemical genomic screening identifies novel therapeutic strategies for cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/26/2019)... ... July 25, 2019 , ... ... the first mixed reality headsets to include a new generation eye tracker with ... in Los Angeles, California (July 30 - August 1). SIGGRAPH attendees will ...
(Date:7/23/2019)... Conn. (PRWEB) , ... July 23, 2019 , ... ... that provides personalized, easy-to-understand, web-based genetic counseling, today announced that the company has ... related to MUTYH-associated polyposis (MAP), familial hypercholesterolemia (FH), and Parkinson’s disease. , The ...
(Date:7/23/2019)... ... July 23, 2019 , ... NanoFUSE is pleased ... strip indicated for spine and orthopedic use. Bioactive glass is a calcium phosphate ... been clinically-proven in orthopedics for over 30 years and now NanoFUSE Biologics has ...
Breaking Biology News(10 mins):
(Date:8/6/2019)... ... August 06, 2019 , ... The ... the launch of a community project that will engage middle and early high ... project, entitled “A Youth-Led Citizen Science Network for Community Environmental Assessment.” Collaborative partners ...
(Date:7/19/2019)... (PRWEB) , ... July 18, 2019 , ... ... Instrumente) announced their investment to enlarge their current piezo motion facilities in Lederhose, ... offer 3 floors for multilayer piezo ceramic assembly production in addition to general ...
(Date:7/11/2019)... VEGAS (PRWEB) , ... July 11, 2019 , ... At ... R3 provided complimentary regenerative therapies to eight military Veterans under the R3 Heroes Program. ... being complimentary. , The R3 Heroes Program allow anyone to nominate a military Veteran, ...
(Date:6/18/2019)... N.J. (PRWEB) , ... June 17, 2019 , ... ... announced that they have entered into an agreement for production and manufacturing of ... for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for ...
Breaking Biology Technology:
Cached News: